How to Read a Peptide Study

Most people encounter peptide research through a summary of a summary. This guide is for reading the thing itself. Nine questions, in the order worth asking them.

1. What species?

The first line of the methods section frequently settles the whole argument. A result in rats is a result in rats.

This is not pedantry. The attrition rate between promising animal results and successful human trials is severe across all of drug development. Animal work is how candidates are identified; it is not how effects in humans are established.

2. Was there a control group, and how were subjects assigned?

Without a control group there is no comparison, and without randomisation the comparison is confounded by whatever determined group assignment.

The strongest design is randomised, double-blind and placebo-controlled. Anything less has a specific known failure mode, and the paper should acknowledge it.

3. What was the primary endpoint, and was it pre-specified?

A trial declares in advance what it is measuring. That is what it is powered for and what its statistics are valid for.

When a report leads with a measure that was not the primary endpoint, something happened. Sometimes the explanation is innocent. Often the primary endpoint did not deliver.

4. Surrogate or clinical?

A surrogate endpoint is a measurement believed to correlate with something that matters: a hormone concentration, a scan finding, a biomarker.

A clinical endpoint is something that matters directly: a heart attack, a hospitalisation, a death, a functional capacity.

CJC-1295 raises growth hormone and IGF-1 — a surrogate result, solidly established. Whether raising them produces any benefit is a clinical question that was never tested. The history of medicine contains many surrogates that moved in the right direction while the clinical outcome moved in the wrong one.

5. How many subjects, and for how long?

Small studies produce unstable estimates. Short studies cannot detect effects that take time to appear — in either direction.

For a chronic condition, a twelve-week trial tells you about twelve weeks.

6. What does the effect size mean?

"Statistically significant" means the result is unlikely to be chance. It says nothing about whether the difference is large enough to matter.

Look for absolute numbers. A relative risk reduction of 50% sounds decisive; if the underlying rate moved from 0.2% to 0.1%, one thousand people would need treating to prevent one event.

7. Who paid, and who wrote it?

Funding and authorship do not invalidate research, and demanding otherwise would eliminate most of pharmacology. But they belong in the assessment.

The relevant pattern is concentration: when nearly every paper on a compound comes from the group that discovered it, with little independent replication, the literature has not been stress-tested — regardless of how many papers it contains.

8. Has anyone unaffiliated reproduced it?

The single strongest signal in any literature. Independent replication by a group with no stake in the outcome is worth more than ten additional papers from the originating laboratory.

9. What did the authors say in the limitations section?

Researchers are usually candid about the weaknesses of their own work, in a paragraph near the end that press releases never quote. Read it first if you are short of time.

The shortcut

If you only have a minute: species, control group, endpoint. Those three answers tell you what a study can support, and they are almost always in the abstract.

Every study summary on Peptide Insider states the design, the population, the findings and the limitations in a fixed format, so these questions can be answered without leaving the page. The reasoning behind our grading is set out in the evidence ratings methodology.